ABBVIE INC.
ABBV XNYS
$288.24
-6.89 (-2.34%)
▼
15-min delayed
Open
$298.74
High
$302.93
Low
$287.71
Volume
7.97M
Market Cap
$521.15B
About ABBVIE INC.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.
Earnings & Analyst Ratings
Next Earnings:
Tue, Feb 2, 2027
Calendar →
TickerDaily Coverage
Stock Market Today, October 18, 2026: Week Ahead Preview — Tech Earnings Dominate
Market News
David Brooks · Oct 19, 2026
The stock market heads into a pivotal earnings week with major tech and industrial names reporting....
Healthcare Stocks This Week: XLV Outpaces S&P 500 Amid Rate Pause Optimism (Oct 5–9, 2026)
Market News
David Brooks · Oct 9, 2026
The healthcare sector navigated a volatile week with conviction, as the XLV ETF gained 2.8% from...
Healthcare Stocks This Week: XLV Gains 2.1% as UNH, LLY Lead Sector Rally (Aug 3–7, 2026)
Market News
David Brooks · Aug 7, 2026
The healthcare sector finished the week with solid momentum, as the Health Care Select Sector SPDR...
Stock Market Today, July 19, 2026: Earnings Bonanza Looms — AMZN, AAPL, MSFT Lead Week
Market News
David Brooks · Jul 20, 2026
The stock market enters a pivotal earnings week starting Monday, July 27, with mega-cap tech titans...
Healthcare Stocks This Week: XLV Outperforms on Rate Cut Bets — Weekly Roundup (Jun 29 – Jul 3, 2026)
Market News
David Brooks · Jul 3, 2026
The healthcare sector capped a record-breaking first half with a strong week as XLV rallied on...
View All Coverage →
Get ABBV Alerts
Stay ahead with breaking news, price alerts, and expert analysis on ABBVIE INC..
Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.